Zymeworks Outlines Strategic Priorities and Outlook for 2024 and 2025

Zymeworks Announces Additional Leadership Appointments

Zymeworks Announces $50 Million Private Placement to EcoR1 Capital

Zymeworks Added to Nasdaq Biotechnology Index

Updated Phase 2a Data Showcasing Potential of Zanidatamab in HER2+/HR+ Metastatic Breast Cancer Presented at SABCS 2023

Zymeworks is pleased to announce, along with our partners Jazz Pharmaceuticals, updated data from the Phase 2a trial of investigational zanidatamab, a HER2-targeted bispecific antibody, in combination with palbociclib, a CDK4/6 inhibitor, and fulvestrant, a selective estrogen receptor antagonist, in patients with HER2-positive (HER2+)/HR-positive (HR+) metastatic breast cancer (mBC) as part of a late-breaking oral […]
Zymeworks Announces Participation in Upcoming Investor Conference

Zymeworks Provides Corporate Update And Reports Third Quarter 2023 Financial Results

Zymeworks Presents Preclinical Data on Trispecific T Cell Engager Therapeutic Programs at the Society for Immunotherapy of Cancer (SITC) Conference

We are pleased to present preclinical data associated with our Trispecific T Cell Engager (TriTCE) therapeutic programs in two poster presentations at the annual SITC Conference, taking place November 1-4 in San Diego, CA. The poster presentation titled “TriTCE Co-Stim: A novel trispecific T cell engager platform, with integrated CD28 costimulation, engineered to widen the […]
Zymeworks Announces Participation in Upcoming Investor Conferences

Zymeworks Showcases Updated Clinical Data for Zanidatamab at the 2023 ESMO Annual Congress

Zymeworks is pleased to announce, along with our partners Jazz Pharmaceuticals and BeiGene, updated data from two ongoing clinical trials evaluating zanidatamab, a HER2-targeted bispecific antibody for the treatment of solid tumors, at the European Society of Medical Oncology (ESMO) Annual Congress taking place October 20-24 in Madrid, Spain. Poster Presentation Information: Title: Zanidatamab (zani) […]
Zymeworks To Host Third Quarter 2023 Results Conference Call

Zymeworks Announces New Director Nominee
